Pyridostigmine bromide
Based on 2 publication(s) in Google Scholar
Pyridostigmine bromide is an orally active cholinesterase (ChE) inhibitor that can be used in cardiovascular disease research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.86%
- CAS. Nr.: 101-26-8
- Formel: C9H13BrN2O2
- Molecular Weight:261.12
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Pyridostigmine bromide
More
Biologische Aktivität
|
AChE |
Pyridostigmine bromide (10-80 ng/mL, 3-72 hours) at low concentrations (10-40 ng/mL) enhances SH-SY5Y cell activity and mitochondrial activity, while at high concentration (80 ng/mL) it inhibits cell viability[5]. Pyridostigmine bromide (60-80 ng/mL, 72 hours) promotes the accumulation of SH-SY5Y cells in the S phase[5]. Pyridostigmine bromide (40-80 ng/mL, 24 hours) upregulates the expression of the telomerase gene, p53 gene, and DNMT1 gene in SH-SY5Y cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y neuroblastoma cells
-
Concentration:10, 20, 40, 60, 80 ng/mL
-
Incubation Time:3 hours, 24 hours, and 72 hours
-
Result:Promoted cell proliferation and mitochondrial activity at low doses (10-40 ng/mL); Reduced cell viability at high dose (80 ng/mL).
-
Cell Line:SH-SY5Y neuroblastoma cells
-
Concentration:10, 20, 40, 60, 80 ng/mL
-
Incubation Time:72 hours
-
Result:Increased proportion of cells in S phase at high doses (>60 ng/mL).
-
Cell Line:SH-SY5Y neuroblastoma cells
-
Concentration:40, 80 ng/mL
-
Incubation Time:24 hours
-
Result:Upregulated telomerase gene at 40 ng/mL; Increased p53 and DNMT1 expression at 80 ng/mL.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mouse model[3]
-
Dosage:1 and 3 mg/kg
-
Administration:Subcutaneous injection (s.c.), once daily for 7 days
-
Result:Reduced blood acetylcholinesterase activity, no effect on cardiovascular function or behavior.
-
Animal Model:Trypanosoma cruzi infection-induced chronic Chagas cardiomyopathy in C57BL/6J mice[4]
-
Dosage:30 mg/kg
-
Administration:Oral gavage (p.o.), once daily, for one month
-
Result:Reduced myocardial inflammatory infiltration, fibrosis, and hypertrophy.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 101-26-8
-
Appearance Solid
-
Molecular Weight 261.12
-
Formel C9H13BrN2O2
-
Color White to off-white
-
SMILES
C[N+]1=CC=CC(OC(N(C)C)=O)=C1.[Br-]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
2024 Jul 2;121(27):e2402143121. PMID: 38923993 -
Mol Med Rep
Treatment with human placental extracts inhibits allergic rhinitis by modulating AMPK/SHP1/SHP2/STING signaling. [Abstract]2025 Jul;32(1):183. PMID: 40280106
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (191.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 8.8 mg/mL (33.70 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (382.97 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Gales BJ, et al. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8. Epub 2007 Feb 6. [Content Brief]
[2]. Kanjwal K, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011 Jun;34(6):750-5. [Content Brief]
[3]. Bernatova I, et al. Effect of chronic pyridostigmine bromide treatment on cardiovascular and behavioral parameters in mice[J]. Pharmacology Biochemistry and Behavior, 2003, 74(4): 901-907. [Content Brief]
[4]. de Cuba MB, et al. Effects of cholinergic stimulation with pyridostigmine bromide on chronic chagasic cardiomyopathic mice. Mediators Inflamm. 2014;2014:475946. [Content Brief]
[5]. Azzolin VF, et al. Effects of Pyridostigmine bromide on SH-SY5Y cells: An in vitro neuroblastoma neurotoxicity model. Mutat Res Genet Toxicol Environ Mutagen. 2017 Nov;823:1-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.8297 mL | 19.1483 mL | 38.2966 mL | 95.7414 mL |
| 5 mM | 0.7659 mL | 3.8297 mL | 7.6593 mL | 19.1483 mL | |
| 10 mM | 0.3830 mL | 1.9148 mL | 3.8297 mL | 9.5741 mL | |
| 15 mM | 0.2553 mL | 1.2766 mL | 2.5531 mL | 6.3828 mL | |
| 20 mM | 0.1915 mL | 0.9574 mL | 1.9148 mL | 4.7871 mL | |
| 25 mM | 0.1532 mL | 0.7659 mL | 1.5319 mL | 3.8297 mL | |
| 30 mM | 0.1277 mL | 0.6383 mL | 1.2766 mL | 3.1914 mL | |
| DMSO | 40 mM | 0.0957 mL | 0.4787 mL | 0.9574 mL | 2.3935 mL |
| 50 mM | 0.0766 mL | 0.3830 mL | 0.7659 mL | 1.9148 mL | |
| 60 mM | 0.0638 mL | 0.3191 mL | 0.6383 mL | 1.5957 mL | |
| 80 mM | 0.0479 mL | 0.2394 mL | 0.4787 mL | 1.1968 mL | |
| 100 mM | 0.0383 mL | 0.1915 mL | 0.3830 mL | 0.9574 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pyridostigmine bromide Related Classifications
HY-B0207A Related Classifications
Powered by Bioz